Tirzepatide vs Semaglutide: Weight Loss Comparison

How They Work

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating. It signals insulin release, suppresses appetite through the hypothalamus, and slows gastric emptying so food stays in the stomach longer. Semaglutide mimics this hormone with a half-life of about seven days, which allows for once-weekly dosing. The appetite suppression is the primary driver of its weight loss effects.

For the full pharmacology, see our semaglutide research profile.

Tirzepatide activates the same GLP-1 receptor, but it also engages a second target: the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone, and for years it was considered a secondary player in obesity research. Tirzepatide’s clinical results changed that view. The GIP receptor contributes to fat metabolism and energy balance through pathways distinct from GLP-1, and preclinical evidence indicates the two receptors produce synergistic effects when activated together.

Our tirzepatide research profile covers the dual mechanism in detail.

Weight Loss: SURMOUNT vs STEP

SURMOUNT-1 and STEP 1 are the pivotal trials for obesity. Both enrolled adults with obesity or overweight with at least one weight-related comorbidity. Both measured percentage change in body weight as the primary endpoint.

SURMOUNT-1 (NEJM, 2022) randomized 2,539 participants to tirzepatide at 5mg, 10mg, or 15mg, or placebo, over 72 weeks. STEP 1 (NEJM, 2021) randomized 1,961 participants to semaglutide 2.4mg or placebo over 68 weeks.

The pattern is clear. Tirzepatide at its lowest dose produced weight loss that matched semaglutide at its highest approved dose. At 10mg and 15mg, it pulled ahead substantially. More than half of participants on 15mg lost at least 20% of their body weight, a threshold previously associated almost exclusively with bariatric surgery.

What happens when you stop? SURMOUNT-4 tracked participants who switched from tirzepatide to placebo after 36 weeks. They regained roughly half of the weight they had lost over the following year. STEP 4 showed a similar rebound pattern for semaglutide. Both drugs appear to require continued use to maintain their effects.

Head-to-Head: SURPASS-2

SURPASS-2 is the only published trial that directly compared tirzepatide and semaglutide in the same study. It enrolled 1,879 adults with Type 2 diabetes already on metformin. Participants were randomized to tirzepatide at 5mg, 10mg, or 15mg, or semaglutide at 1mg, for 40 weeks.

Every tirzepatide dose outperformed semaglutide on both HbA1c and weight. The differences were statistically significant across all comparisons.

Side Effects

The adverse event profile is similar for both compounds. GI symptoms are the dominant concern and tend to diminish with gradual dose escalation.

Cardiovascular Evidence

Both compounds improve cardiometabolic markers including blood pressure, triglycerides, and systemic inflammation. But for hard cardiovascular outcomes, semaglutide currently has stronger data.

The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in people with obesity and established cardiovascular disease, without requiring a diabetes diagnosis.

That result is the first completed cardiovascular outcomes trial for a GLP-1 agonist in a non-diabetic obesity population. Tirzepatide’s equivalent trial (SURPASS-CVOT) is ongoing. Secondary endpoints from existing tirzepatide trials suggest similar cardiovascular benefits, but the definitive event-driven data has not been published.

The Bottom Line

For weight reduction, tirzepatide produces superior results. The margin is consistent across all dose levels and across both obesity and diabetes populations where data exists. The dual-receptor mechanism translates into a measurable clinical advantage.

For glycemic control in Type 2 diabetes, tirzepatide also has the edge in the available head-to-head data, with the caveat that the comparison used a lower semaglutide dose than what is approved for obesity.

For cardiovascular risk reduction, semaglutide holds the advantage today. The SELECT trial provides hard outcomes data that tirzepatide has not yet matched.

Tolerability is comparable between the two. Neither is clearly better or worse in terms of side effects.

Neither compound is categorically superior in every dimension. Both represent a substantial advance in metabolic research. The relevant question is which evidence base matters most for the specific research context, and the data presented above should provide a clear foundation for making that assessment.

For complete profiles including molecular data, dosing information, and literature references, see our research pages on tirzepatide and semaglutide. For the next generation of multi-agonist peptides, our retatrutide profile covers the triple-receptor approach now in Phase 3 trials.

This article is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before making health-related decisions. Clinical trial data referenced here is sourced from peer-reviewed publications and may not reflect the most current findings.